Coley Pharmaceutical Group Updates Hepatitis C Drug Development Strategy

Tue, 23 Jan 2007 02:00 PM EST

... Coley Pharmaceutical Group, Inc. (Nasdaq: COLY) today announced that the company has made the strategic decision to suspend the independent development of ACTILON, its product candidate for the treatment of Hepatitis C virus (HCV) infection. [click link for full article] ...